Proactive Investors - Run By Investors For Investors

Breakfast News - AIM Breakfast : InnovaDerma, Osirium Technologies, Rex Bionics PLC, Ariana Resources plc, Inspiration Healthcare, REDT Energy, Action Hotels PLC, Pennant International, Silence Therapeutics plc, UK Oil & Gas Investments PLC

Breakfast News - AIM Breakfast : InnovaDerma, Osirium Technologies, Rex Bionics PLC, Ariana Resources plc, Inspiration Healthcare, REDT Energy, Action Hotels PLC, Pennant International, Silence Therapeutics plc, UK Oil & Gas Investments PLC

What’s cooking in the IPO kitchen?

Velocity Composites—Schedule 1. Manufactures advanced carbon fibre and ancillary material kits (predominantly carbon fibre) for use in the production of aircraft.  Mid May admission expected. Offer details TBC.

Shearwater Group—Schedule 1. Acquiring SecureEnvoy for £20m in cash and shares—a provider of multifactor authentication enterprise software solutions. RTO under the AIM rules.

ADES International— Provider of offshore and onshore oil and gas drilling and production services in the Middle East and Africa, seeking raise up to $170m plus vendor sale under a Standard Listing of the Main Market. Admission due May 2017.

Global Ports Holding—Intention to float on Standard List of the Main Market.  International cruise ports operator. Seeking $200m+ raise including $75m primary offer. Expected price range 735p to 875p. Mkt cap up to £539m.

Verditek— Schedule 1 update. On Admission, the Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Issue price 10p.  Admission in May.

Tufton Oceanic Assets– Offer extended to 9 May on specialist funds segment of  Main Market to enable investors to complete further due diligence.

  

Breakfast buffet

InnovaDerma* (LON:IDP) 226p £23m

The UK developer of life sciences, beauty and personal care products  has announced a new e-tailer distribution deal with ASOS plc, one of the largest global online fashion and beauty stores attracting hundreds of millions of visitors in the UK and internationally on its website. Skinny Tan will be available on ASOS from June and will be marketed and distributed globally by ASOS. Trading continues to be very robust and revenue growth has continued on its positive momentum with April achieving the highest-ever monthly revenue. The Company is also a finalist for the IPO of the Year award at the Small Cap Awards to be held on 22 June 2017. NED Clifford Giles has resigned for personal reasons and an independent NED is being sought.

Rex Bionics (LON:RXB) 5.5p £1.4m

The pioneer of the REX™ Robot technology that enhances the mobility of wheelchair users, announced that Rex Bionics Group companies have entered into various agreements, the combination of which will result in a major restructuring of the Rex Group as indicated in the outline plan described in the Company's announcement of 13th March 2017. Subject to GM. On completion of the proposed transaction, the Company would have a 36% shareholding in an Australian company  (Rex Pty) that will own all the technology and assets that support the REX robotic mobility aid and can access funding to promote technological innovation in Australia.  ‘BML’ a fund management company based in Melbourne to invest £4.4m in Rex Pty and a further £1.5m subject to milestones. RXB has right to follow investment on a pro-rata basis.

Osirium Technologies (LON:OSI) 124.5p £12.94m

14 month results to December 2016. Total Revenue of £477,577 (2015: £290,150), comprising: SaaS Revenue of £440,582 (2015: £252,430). Operating loss of £1,822,497 (2015: £847,138), primarily reflecting increased investment in sales and marketing and additional headcount in the R&D and Customer Support teams. Cash of £3.6m. Revenue growth slower than expected at IPO but “2016 has provided a strong foundation for the year ahead. As evidenced by our recent new customer wins, we are now seeing the signs of significant progress.” Three new customers won in the first few months of 2017: one of the world's largest insurance companies, a critical national infrastructure business and a retail mobile technology provider. There are no market forecasts.

Inspiration Healthcare Group (LON:IHC) 55p £16.87m

FYJan17 results from the global medical device company. Revenue increased by 9.4% to £14.3 million. Underlying operating profit £1.2m. Major restructuring includes Inditherm product manufacturing outsourced, Rotherham factory closed, New corporate head office opened in Crawley.  Adapting to more stringent regulatory requirements which will but a brake on growth short term. ‘The impact of Brexit and the value of sterling still presents some challenges to a company of our size that both imports and exports goods. Our cash reserves and cash collection remain strong and we believe that we are well positioned for the year ahead. Our expectations for underlying full year growth remain robust and unchanged albeit new product growth will inevitably be slowed’.   No market forecasts.

Ariana Resources (LON:AAU) 1.75p £15.7m

Increase & update of  JORC compliant Mineral Resource estimate for  Kiziltepe Project following  recent drilling programme in Turkey. Increase in global Mineral Resource estimate to a total of c. 257,500 oz Au and 4.87Moz Ag contained metal on 4 main veins & several subsidiary veins (c. 338,500 oz Au equivalent). Substantial increase in tonnage to c. 3.8Mt following inclusion of all subsidiary veins drill tested to date, which do not currently form part of the mine plan.   JORC Exploration Target of up to a further c. 1.25Mt @ 1.8 g/t Au and 31 g/t Ag established for vein extensions across Kiziltepe that have not yet been drill tested. Total resource within the Red Rabbit Project Area and surrounding projects now stands at 605,000 oz gold equivalent.

redT Energy (LON:RED) 10p £65.4m

The energy storage technology company, has signed an agreement with the Royal National Lifeboat Institution ("RNLI") for a 180 kWh unit for  installation at the RNLI's Inshore Lifeboat Centre in East Cowes on the Isle of Wight. The site is used to manufacture and maintain the RNLI's fleet of inshore lifeboats. redT's energy storage machine will be used to capture excess electricity and time-shift it for use for the manufacture and maintenance of RNLI craft.  In the future, the RNLI will be able to build portions of boats using 100% solar energy, for example the hull curing ovens can be completely powered by solar power. FYDec17E £10.6m revenue, Pre-tax loss £7.5m.

Pennant International (LON:PEN) 91.5p £30.14m

The supplier of integrated logistic support solutions, products and services, principally to the defence, rail, aerospace and naval sectors and to Government Departments, confirmed that its wholly owned subsidiary, Pennant Training Systems Limited, has been notified that Lockheed Martin UK) Limited, the UK subsidiary of the Lockheed Martin Corporation, one of the world's leading aerospace and defence contractors, has exercised its option to increase the value of the contract announced on 16 June 2016, from its initial value of £0.2m to in excess of £2.2m.  This extension is scheduled for delivery across 2017 and 2018 and is supportive of current expectations.  FYDec17E £18m rev, PBT £2.4m.

Silence Therapeutics (LON:SLN) 78p £54.59m

The specialist in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has presented new pre-clinical data generated using its GalNAc-siRNA platform technology, including the translation of effective liver target knockdown into higher species, at the TIDES: Oligonucleotides and Peptide Therapeutics meeting in San Diego. The presentation is available on the Company's website, www.silence-therapeutics.com.

Action Hotels (LON:AHCG) 37.5p £55.36m

The owner, developer and asset manager of branded three and four-star hotels in the Middle East and Australia, has chosen Novotel as the brand partner for its new hotel, Novotel Melbourne South Wharf, located at the Melbourne Convention and Exhibition Centre. The hotel, which is due to be completed in Q1 2018, will comprise 347 rooms, 30 more rooms than originally announced, making it the second largest hotel in Action's portfolio. This brings Action's total operating rooms and development pipeline to 3,214 rooms and once opened, will be Action's fourth property in Australia and third in Melbourne.

UK Oil & Gas Investments (LON:UKOG) 1.27p £33.12m

In order to progress the acquisition of new site-specific hydrogeological data over and around the Markwells Wood drilling pad, the Company has temporarily withdrawn its planning application to the South Downs National Park Authority. The application is now planned for resubmission later in 2017 after the completion of the planned data acquisition and upon the conclusions of ongoing technical conversations with the Environment Agency.  The Company now also intends to take this opportunity to apply for a full EA permit covering phase 1 of the proposed development, with a view to including this as part of the resubmission of the planning documents.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use